Personalis (NASDAQ:PSNL) Announces Earnings Results, Beats Expectations By $0.09 EPS

Personalis (NASDAQ:PSNL) posted its earnings results on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.09, Zacks reports. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Personalis updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Personalis Price Performance

Personalis stock traded down $0.24 during midday trading on Thursday, reaching $4.24. The company’s stock had a trading volume of 1,216,074 shares, compared to its average volume of 1,158,614. Personalis has a 52-week low of $1.13 and a 52-week high of $7.20. The stock has a market capitalization of $299.55 million, a P/E ratio of -2.52 and a beta of 1.73. The stock’s 50-day simple moving average is $5.45 and its 200-day simple moving average is $5.04.

Wall Street Analyst Weigh In

Several analysts have issued reports on PSNL shares. Lake Street Capital upped their price target on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $7.25 price target on shares of Personalis in a research note on Wednesday, January 8th. Finally, HC Wainwright decreased their price objective on shares of Personalis from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, January 27th.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.